Sangamo’s Gene Regulation Technology Reduces Alzheimer’s-linked Tau Protein

Sangamo’s Gene Regulation Technology Reduces Alzheimer’s-linked Tau Protein
Sangamo Therapeutics' gene regulation technology significantly reduced levels of tau – a protein crucial to Alzheimer’s disease (AD) – in laboratory tissue experiments and a mouse model, the company announced. Sangamo's collaborators from the Massachusetts General Hospital Alzheimer's Disease Research Center and Harvard Medical School presented the results at the 13th International Conference on Alzheimer's & Parkinson's Diseases in Vienna. In addition to extracellular amyloid plaque, accumulation of tau protein and neurofibrillary tangles in the brain are hallmarks of Alzheimer's. The tangles ultimately lead to neuronal dysfunction and loss. Reducing tau levels protects neurons and may reverse the disease, research has shown. "Tau protein plays a critical role in certain devastating neurodegenerative diseases, including dementias such as AD, and studies point to the potential for tau reduction to prevent neuronal loss and possibly even reverse Alzheimer's disease pathology," Bradley Hyman, MD, PhD, said in a press release. Hyman is the director of the Massachusetts Alzheimer's Disease Research Center and of the Alzheimer's Unit at the MassGeneral Institute for Neurodegenerative Disease. He is also a neurology professor at Harvard Medical School. The study involved Sangamo's zinc finger protein transcription factor (ZFP-TF)-mediated gene regulation technology. ZFP-TF selectively rep
Subscribe or to access all post and page content.

2 comments

    • Jose Marques Lopes says:

      Dear Ina, thank you for your question. ZPF-TF development is most advanced in Huntington’s Disease, of which promising pre-clinical results were presented in 2014. However, the technology is still being developed by Sangamo Therapeutics and Shire aiming to proceed to clinical trials in the future.

Leave a Comment

Your email address will not be published. Required fields are marked *